Azurity Pharmaceuticals v. Accord Healthcare: Voluntarily Dismissed in 82 Days
Azurity Pharmaceuticals and EMP Levo US filed suit in Delaware against Accord Healthcare asserting US9050307B2, covering a method for preparing a levothyroxine solution. Plaintiffs voluntarily dismissed all claims just 82 days after filing, before Accord served any answer or dispositive motion.
Early voluntary dismissal before Accord Healthcare entered a defence
On 31 March 2023, Azurity Pharmaceuticals, Inc. and EMP Levo US, B.V. filed an infringement action in the Delaware District Court against Accord Healthcare, Inc. The single patent asserted was US9050307B2, directed to a method for the preparation of a levothyroxine solution — a narrow-margin pharmaceutical formulation space subject to ongoing ANDA-driven litigation. Judge Colm F. Connolly was assigned to the case.
The recorded basis of termination is Voluntary dismissal. The docket order states that plaintiffs filed a notice of dismissal pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, dismissing all claims without prejudice, and expressly noting that Accord Healthcare had not yet served an answer or motion for summary judgment at the time of filing. The specific terms driving the dismissal are not disclosed in the available record.
The 82-day duration and pre-answer timing of the dismissal are notable: Rule 41(a)(1)(A)(i) permits unilateral dismissal by the plaintiff as of right before an answer or summary-judgment motion is served, requiring no court order. Whether the dismissal reflects a commercial resolution, a strategic re-filing decision, or a change in regulatory posture is not determinable from the public record.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 82 days
82 days — from filing to voluntary dismissal, well under the median ANDA patent dispute timeline
US9050307B2 — Method for the preparation of a levothyroxine solution
Any pharmaceutical manufacturer, ANDA applicant, or contract development organisation developing a levothyroxine solution product should treat US9050307B2 as an active FTO risk. The patent was not invalidated or narrowed in this proceeding — the case ended without any merits ruling. If your formulation process overlaps with the preparation method claimed, you carry direct infringement exposure. This applies to generic drug developers, CMOs, and any party sourcing a levothyroxine liquid formulation from a third-party manufacturer.
Official order — verbatim text
The notice of dismissal was filed under Rule 41(a)(1)(A)(i) and states all claims are dismissed without prejudice, with the express notation that Accord had not yet served an answer or dispositive motion. This means the dismissal took effect automatically on filing, without requiring any court order, and leaves US9050307B2 untested on validity or infringement in this proceeding.
Voluntarily dismissed: what the dismissal means for both parties
Rule 41(a)(1)(A)(i): unilateral dismissal as of right
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss an action without a court order by filing a notice of dismissal before the opposing party serves an answer or a motion for summary judgment. Because Accord had not yet done either, Azurity and EMP Levo could exit the litigation unilaterally. The public record does not specify whether the dismissal was with or without prejudice in any agreed instrument beyond the notice itself.
Pre-answer voluntary exitWithout prejudice — but the distinction matters
The notice of dismissal states all claims are dismissed without prejudice, meaning the plaintiffs are not barred from re-filing the same infringement claims on US9050307B2 against Accord in a future action. A dismissal with prejudice would have acted as a final adjudication on the merits. The public record confirms the dismissal is without prejudice; no further qualifying terms are disclosed.
Re-filing not foreclosedAccord exits without a merits ruling — but remains exposed
Accord Healthcare faces no judgment and no admission of infringement. However, the without-prejudice nature of the dismissal means it cannot rely on this case as a bar to future suit on US9050307B2. If Accord's ANDA process continues, the patent holders retain the option to re-assert. No costs or fees order in favour of Accord has been recorded in the available docket.
No merits adjudicationLevothyroxine IP: patent exposure remains live for generic entrants
The voluntary pre-answer dismissal leaves US9050307B2 unchallenged on the merits. For other generic manufacturers developing levothyroxine solution products, the patent remains enforceable and its validity has not been tested in this proceeding. Companies in this formulation space should treat the patent as an active risk and conduct FTO analysis accordingly.
Patent validity untestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | EMP Levo US, B.V. | Individual | Search in Eureka ↗ |
| Defendant | Accord Healthcare, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Ian Robert Liston | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jennifer A. Ward | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jody Karol | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kristina M. Hanson | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Wendy L. Devine | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Wilson Sonsini Goodrich & Rosati PC | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the levothyroxine pharmaceutical formulation space
Forward-looking patent and innovation intelligence for the levothyroxine solution sector, based on the portfolios and technology domains active in this Delaware case.
Azurity's levothyroxine and liquid formulation patent activity
Azurity Pharmaceuticals has built a portfolio in paediatric and liquid pharmaceutical formulations. Understanding the breadth of their filings beyond US9050307B2 — including continuation applications and related method claims in the thyroid hormone space — is essential for competitors assessing white-space or clearance for novel levothyroxine preparation processes.
Formulation patent portfolioFiling trends in levothyroxine solution preparation methods
The levothyroxine solution formulation space has seen multiple patent filings focused on stability, bioavailability, and manufacturing process improvements. Mapping recent application trends in this area can reveal which preparation method parameters — pH control, excipient selection, dissolution steps — are attracting the most new IP filings and where design-around opportunities exist.
Formulation IP trendsAccord Healthcare's patent landscape in generic pharma
Accord Healthcare is an active generic pharmaceutical manufacturer with ANDA filings across multiple therapeutic categories. Assessing Accord's own patent filings and any declared process innovations in liquid oral formulations can indicate how they are positioning their manufacturing IP relative to branded patent holders like Azurity in the levothyroxine space.
Generic pharma IP watchAdjacent R&D opportunities near levothyroxine method claims
Method-of-preparation patents like US9050307B2 often leave adjacent white space in formulation optimisation, device-integrated delivery, or alternative solvent systems. Identifying claim gaps in the levothyroxine liquid formulation patent landscape may reveal patentable innovation opportunities for R&D teams developing next-generation thyroid hormone replacement products.
Formulation white spaceSimilar levothyroxine and pharmaceutical solution patent cases in Delaware
Explore related pharmaceutical formulation patent infringement cases litigated in the Delaware District Court, particularly those involving levothyroxine or narrow-margin ANDA-driven disputes.
What this case signals for the levothyroxine pharmaceutical IP landscape
An early, pre-answer dismissal in a pharmaceutical patent case rarely signals indifference — it typically marks a pivot worth tracking.
Pre-answer dismissals preserve maximum optionality for patent holders
By exiting under Rule 41(a)(1)(A)(i), Azurity and EMP Levo avoided any adverse ruling, claim construction, or invalidity record. US9050307B2 remains unscathed. Generic competitors should not interpret dismissal as abandonment — the patent is fully enforceable and re-litigation risk is real.
Accord's ANDA status remains the key variable to monitor
The trigger for most levothyroxine solution patent suits is ANDA filing activity. The dismissal before Accord answered means the underlying regulatory timeline — not the litigation — is likely driving strategy. Tracking Accord's FDA submissions on levothyroxine solution products is the most direct signal of re-litigation risk.
Azurity v Accord — key questions answered
The case was voluntarily dismissed. Plaintiffs Azurity Pharmaceuticals and EMP Levo US filed a notice of dismissal under Rule 41(a)(1)(A)(i), dismissing all claims without prejudice on 21 June 2023, approximately 82 days after filing. Accord Healthcare had not served an answer or motion for summary judgment at the time of dismissal.
The single patent asserted was US9050307B2 (application number US14/003598), directed to a method for the preparation of a levothyroxine solution. The patent was not adjudicated on the merits — the case ended before any substantive court ruling on validity or infringement.
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss an action as of right — without needing a court order — by filing a notice before the defendant serves an answer or motion for summary judgment. A dismissal without prejudice means the plaintiff is not barred from re-filing the same claims in a future action. No merits determination is made.
No. Because the dismissal occurred before any merits ruling, US9050307B2 was not invalidated, narrowed, or otherwise affected by this proceeding. The patent remains enforceable, and the patent holders retain the right to assert it in future litigation. Generic manufacturers in the levothyroxine solution space should treat it as an active IP risk.
The plaintiffs are Azurity Pharmaceuticals, Inc., a US specialty pharmaceutical company, and EMP Levo US, B.V., a Netherlands-registered entity. Both are recorded as co-plaintiffs asserting US9050307B2. The specific nature of the relationship between the two entities — including any licensing or co-ownership arrangement — is not disclosed in the available public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.